Clinical Trials on Central Venous Catheter Exit Site Infection in Finland

Total 55 results

C. R. Bard

Terminated

The Pristine Post-Market Study

End Stage Renal Disease | Kidney Failure, Chronic | Hemodialysis Access Failure | Hemodialysis Complication | Central Venous Catheter Related Bloodstream Infection | Hemodialysis Catheter Infection

United States
Helsinki University Central Hospital

Completed

Association of Cephalosporin Resistance and Surgical Site Infections in Patients Undergoing Pancreaticoduodenectomy

Surgical Site Infection | Pancreaticoduodenectomy | Biliary Tract Infection Bacterial

Finland
Women and Infants Hospital of Rhode Island

Recruiting

The Effect of Intrawound Vancomycin Powder on Surgical Site Infection in Inguinal Lymph Node Dissection

Postoperative Complications

United States
Helsinki University Central Hospital

Active, not recruiting

Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery (MOBILE2)

Colorectal Neoplasms | Colorectal Cancer | Surgery--Complications | Surgical Site Infection | Colorectal Carcinoma | Rectal Adenocarcinoma | Rectum Neoplasm | Rectum Carcinoma

Finland
Otto Helve
University of Helsinki

Not yet recruiting

Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics (FMT)

Microbial Colonization | Antibiotic Side Effect

Finland
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Ukraine, Canada, Croatia, Georgia, Germany, Poland, Russian Federation
Avenge Bio, Inc

Terminated

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Primary Peritoneal Carcinoma | Neoplasm, Ovarian | Adenocarcinoma Ovary | Serous Adenocarcinoma of Ovary | Serous Adenocarcinoma of Primary Peritoneum | High Grade Serous Adenocarcinoma

United States
TILT Biotherapeutics Ltd.

Recruiting

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL)

Melanoma | Head and Neck Squamous Cell Carcinoma

United States, Finland
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Mixed Adenocarcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
Incyte Corporation

Terminated

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host Disease

United States, Spain, France, Canada, Israel, United Kingdom, Germany, Italy, Denmark, Sweden, Finland, Belgium, Poland, Greece, Austria, Switzerland
Bayer

Completed

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma | Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma | Advanced Recurrent Serous Ovarian Cancer | Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

United States, Sweden, Netherlands, United Kingdom, Finland
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Nausea and Vomiting | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Completed

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal Sarcoma

United States
Volastra Therapeutics, Inc.

Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Gastric Adenocarcinoma | Uterine Carcinosarcoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Transitional Cell Carcinoma of Bladder | Colorectal Adenocarcinoma | Gastroesophageal Junction... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Neutropenia | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Infectious Disorder

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
Pfizer

Terminated

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Low-grade Serous Ovarian Cancer | Low-grade Serous Fallopian Tube Cancer | Low-grade Serous Peritoneal Cancer

United States, Canada, Hungary, Spain, Belgium, France, United Kingdom, Australia, Czechia, Netherlands, Sweden, Italy, Denmark, Germany, Austria, Finland, Ireland, Norway, Poland
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Cavity Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian...

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Cervical Small Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Endometrial Clear Cell Carcinoma | Stage III Endometrial Carcinoma | Cervical... and other conditions

United States, Korea, Republic of, Japan, Canada
SillaJen, Inc.

Completed

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)

Hepatocellular Carcinoma (HCC)

United States, Canada, New Zealand, Australia, China, France, Germany, Hong Kong, Israel, Italy, Korea, Republic of, Portugal, Singapore, Taiwan, Thailand, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

Cervical Intraepithelial Neoplasia

Belgium, France, Spain, United States, Finland, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer... and other conditions

United States
Bioniche Life Sciences Inc.

Terminated

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (EMBARC-RF)

Carcinoma in Situ | Neoplasm Recurrence, Local | Bladder Neoplasm | Mycobacterium | Transitional Cell, Carcinoma

United States, Canada, Poland, Germany, Netherlands, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
US Endoscopy Group Inc.

Completed

trūFreeze® Spray Cryotherapy Patient Registry

Barrett Esophagus | Esophageal Neoplasm | Esophageal Stenosis | Esophageal Dysplasia | Bronchial Neoplasm | Stenosis of Bronchus or Trachea

United States
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology

Completed

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) (AROMA)

Chronic Rhinosinusitis With Nasal Polyposis

United States, Italy, Canada, Japan, Germany, Netherlands

Clinical Trials on Central Venous Catheter Exit Site Infection in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations